Prognostic value of androgen receptor expression in different molecular types of breast cancer in women

Breast Dis. 2022;41(1):495-502. doi: 10.3233/BD-220037.

Abstract

Background: Breast cancer is a common women's disease. Usually, oestrogen is blamed in the aetiology and correlated with the prognosis; however, androgens are recently raising concern about its role in the breast cancer treatment and prognosis.

Methods: In this study we retrieved archival paraffin blocks of breast cancer patients and stained it for androgen. Thereafter, we compared clinico-epidemiologic parameters, histopathology, neoadjuvant response and recurrence rate and pattern among patients with and without androgen receptor (AR) expression.

Results: In total, 119 patients fulfilled enrolment criteria; AR expression were present in 77.3% of the patients. AR expression was associated with less grade III (6.8% versus 36.4%), and less triple negative (6.2% versus 25%), but similar overall recurrence rate (25% versus 22.2%). However, distant recurrence was significantly higher in androgen positive patients (91.3% versus 33.3% of all recurrences).

Conclusion: Androgen expression appears to be common among breast cancer, but with no clear implication in tumour aggressiveness or effect on the rate of recurrence. However, being commonly associated with distant spread may have an impact on survival of the patients.

Keywords: Hormonal receptors; androgen expression; breast cancer recurrence; molecular types.

MeSH terms

  • Androgens
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Prognosis
  • Receptors, Androgen / genetics
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Androgens
  • Receptors, Androgen
  • Biomarkers, Tumor